ROYCE & ASSOCIATES LP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYCE & ASSOCIATES LP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q1 2018$632,000
+45.6%
30,0000.0%0.00%
+33.3%
Q4 2017$434,000
-8.2%
30,0000.0%0.00%0.0%
Q3 2017$473,000
+26.8%
30,0000.0%0.00%
+50.0%
Q2 2017$373,000
-23.6%
30,0000.0%0.00%
-33.3%
Q1 2017$488,000
+7.7%
30,0000.0%0.00%0.0%
Q4 2016$453,000
+287.2%
30,000
+289.6%
0.00%
+200.0%
Q3 2016$117,000
-60.9%
7,7000.0%0.00%
-50.0%
Q2 2016$299,0007,7000.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2018
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders